Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Summary

Oculis (NASDAQ:OCS) announced the vesting and settlement of previously granted restricted stock units (RSUs) to a company director. The notification names Riad Sherif and cites an RSU vesting/settlement event dated 5 April 2026.

The disclosure is a routine insider transaction notice about equity compensation processing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

News Market Reaction – OCS

-0.55%

-0.55% News Effect

On the day this news was published, OCS declined 0.55%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

What This Means

This announcement reports vesting and settlement of previously granted RSUs to a director, a routine...

Analysis

This announcement reports vesting and settlement of previously granted RSUs to a director, a routine governance event that does not change Oculis’s clinical or financial outlook. In context, recent catalysts have centered on Privosegtor’s regulatory designations and pivotal trial plans. Investors may focus on upcoming Phase 3 readouts, prior equity financings disclosed in 2025, and future clinical or regulatory milestones as more material drivers.

Historical Context

5 past events · Latest: Apr 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 07	Investor conferences	Positive	+0.2%	Participation in April 2026 investor conferences highlighting upcoming pivotal readouts.
Mar 31	Regulatory designation	Positive	+8.3%	EMA PRIME designation for Privosegtor following FDA Breakthrough and Orphan status.
Mar 27	Equity incentives	Neutral	-0.6%	Annual equity incentive awards granted to an executive with related disclosure.
Mar 16	Clinical presentation	Positive	+1.6%	Phase 2 ACUITY Privosegtor data presentation at NANOS 2026 meeting.
Mar 16	Insider share purchases	Positive	+1.6%	Notifications of ordinary share purchases by a board member with attached notices.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Oculis headlines, especially R&D and designation milestones, have generally coincided with modestly positive price reactions.

Recent Company History

Over the last month, Oculis has combined clinical and regulatory progress with routine administrative disclosures. Key positives included EMA PRIME designation for Privosegtor on Mar 31, 2026 and presentations of Phase 2 ACUITY data, both followed by price gains. The company also reported recurring notifications of managerial and board transactions, which saw minor moves. Today’s RSU vesting notice fits this pattern of low-sensitivity governance updates alongside a broader, clinically driven story.

Regulatory & Risk Context

Active S-3 Shelf · $6,877,246.59 · Short Interest: 1.22%

Shelf Active

Short Interest

1.22% of shares outstanding

as of 2026-05-29 Days to cover: 1

Active S-3 Shelf Registration 2025-11-10

$6,877,246.59 registered capacity

An effective Form F-3 filed on Nov 10, 2025 registers resale of up to 494,259 warrant shares by a selling securityholder. Oculis is not selling primary shares under this prospectus; it would receive up to $6,877,246.59 only if the warrant is fully exercised for cash.

Key Terms

rsus

1 terms

rsus financial

"The attached notification relates to the vesting and settlement of RSUs previously..."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZUG, Switzerland, April 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

Attachment

• Notification of managers' transaction - Riad Sherif - 5 April 2026 RSU vest

FAQ

What did Oculis (OCS) announce about RSUs on April 8, 2026?

Oculis announced the vesting and settlement of previously granted RSUs to a director, dated 5 April 2026. According to the company, the notification names director Riad Sherif and documents routine processing of equity awards.

Who is the director mentioned in the Oculis (OCS) RSU notification?

The director named is Riad Sherif, associated with an RSU vesting/settlement dated 5 April 2026. According to the company, the filing notified regulators and investors of the managerial transaction.

Does the Oculis (OCS) RSU notice indicate a share issuance or sale?

The notice reports vesting and settlement of RSUs but does not specify a sale or new share issuance. According to the company, the attachment simply documents the managerial transaction for compliance and disclosure.

When did the RSUs for the Oculis (OCS) director vest and settle?

The RSUs vested and settled on 5 April 2026, as stated in the notification. According to the company, the filing dated 8 April 2026 records that vesting/settlement event for regulatory disclosure.

How should investors interpret the Oculis (OCS) RSU settlement disclosure?

Investors should view it as a standard insider compensation disclosure with no new financial guidance or operational updates. According to the company, the filing documents routine vesting and settlement of director RSUs for transparency.